A case of severe increase of liver enzymes in a ATTRv patient after one year of inotersen treatment

BACKGROUND: Inotersen is an antisense oligonucleotide used to treat hereditary transthyretin amyloidosis (ATTRv). The most common drug-related adverse effects (AEs) include thrombocytopenia and glomerulonephritis. Hepatic damage is rare, but liver enzyme monitoring is mandatory. CASE REPORT: A 70-ye...

Descripción completa

Detalles Bibliográficos
Autores principales: Severi, Daniele, Palumbo, Giovanni, Spina, Emanuele, Iovino, Aniello, Nolano, Maria, Manganelli, Fiore, Tozza, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795110/
https://www.ncbi.nlm.nih.gov/pubmed/36576645
http://dx.doi.org/10.1007/s10072-022-06568-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795110/
https://www.ncbi.nlm.nih.gov/pubmed/36576645
http://dx.doi.org/10.1007/s10072-022-06568-w

Ejemplares similares